Skip to main content

Table 1 Characteristics of the enrolled patients

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

 

Total n = 17

Age (years)

59.9 ± 11.7 (30–82)

Sex (male/female)

5/ 12

Disease duration (years)

12.7 ± 10.4 (1–41)

Steinbrocker Stage (I/II/III/IV)

2/0/5/10

Steinbrocker Class (1/2/3/4)

2/9/5/1

MTX (%)/dose of MTX (mg/week)

76.5/ 9.3 ± 3.9 (4.0 - 16.0)

PSL (%)/dose of PSL (mg/day)

64.7/ 5.2 ± 3.7 (1.0 - 15.0)

Tacrolimus (%)/dose of tacrolimus (mg/day)

29.4/ 2.3 ± 0.7 (1.5 - 3.0)

  1. MTX: methotrexate, PSL: prednisolone.